Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 91

Sort by

Sort Order Select

Journal Articles

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Zi-Xun Yan, Wenbin Qian, Ying Lu, Keshu Zhou, Dongmei Ji, Yuhua Li, Dehui Zou, Lanfang Li, Lei Zhang, Ping Li, Hongmei Jing, Chunyan Ji, Ting Niu, Fei Li, Xiaojian Zhu, Jinghua Zhao, Yu Hu, Depei Wu, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 7230.

https://doi.org/10.1182/blood-2025-7230

Published: 2025

Journal Articles

Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL

Lili Zhou, Botao Wang, Ping Li, Yan Lu, Shiguang Ye, Shaoguang Li, Aibin Liang

Blood (2025) 146 (Supplement 1): 7265.

https://doi.org/10.1182/blood-2025-7265

Published: 2025

Journal Articles

A multicenter, single-arm study of camrelizumab combined with rituximab followed by R-CHOP as first-line treatment for young patients with primary extranodal diffuse large B-cell lymphoma: The credit trial

Yan Gao, Xue-Ping Li, Xuan-Ye Zhang, Xiaoxiao Wang, Qichun Cai, Bing BAI, Li-Qin Ping, Ji-Chen Hong, Huiqiang Huang

Blood (2025) 146 (Supplement 1): 5517.

https://doi.org/10.1182/blood-2025-5517

Published: 2025

Journal Articles

A real world study of inotuzumab ozogamicin for the treatment of B-cell acute lymphoblastic leukemia: Multi-center result from SH-ALL group

Yuchen Yan, Ligen Liu, Jie Hao, Xiaofeng Han, Ping Li, Libing Wang, Li Yang, Yong Tang, Cheng Wang, Weiyang Liu, Jiayi Ren, Jiong Hu, Jianmin Yang, Qi Zhu, Aibin Liang, Jian Hou, Xianmin Song, Jianqing Mi, JIN WANG

Blood (2025) 146 (Supplement 1): 6830.

https://doi.org/10.1182/blood-2025-6830

Published: 2025

Journal Articles

Efficacy and safety of a fully human BCMA CAR T-cell therapy for high-risk newly diagnosed transplant-ineligible multiple myeloma: Updated results from an open label, single-arm，phase 1 study（fumanba-2）

Bing Chen, Xiaoyan Shao, Yuanyuan Jin, Yong Xu, Qinglin Shi, Chaoyang Guan, Xuxing Shen, Ping Li, Yujie Wu, Hui Zeng, Yu Zhu, Min Zhou, Lei Fan, Yaqiong Lu, Hongyu Gui, Lijuan Chen

Blood (2025) 146 (Supplement 1): 254.

https://doi.org/10.1182/blood-2025-254

Published: 2025

Journal Articles

Efficacy and safety of chidamide and Bruton tyrosine kinase inhibitors combination therapy in relapsed/refractory diffuse large B-cell lymphoma

Lili Zhou, Bing Li, Shiguang Ye, Yan Lu, Shaoguang Li, Ping Li

Blood (2025) 146 (Supplement 1): 3700.

https://doi.org/10.1182/blood-2025-3700

Published: 2025

Journal Articles

primary efficacy and safety of first-line R-MTO regimen (rituximab, methotrexate, thiotepa, and orelabrutinib) followed by autologous hematopoietic stem cell transplantation in PCNSL

Haichen Wei, Xin Wang, Lijie Xing, Dan Liu, Hui Wang, Ping Li, Zengjun Li

Blood (2025) 146 (Supplement 1): 3687.

https://doi.org/10.1182/blood-2025-3687

Published: 2025

Journal Articles

Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study

Blood (2025) 146 (Supplement 1): 6293.

https://doi.org/10.1182/blood-2025-6293

Published: 2025

Journal Articles

Combination anti-PD1 antibody and rituximab followed by R-CHOP for newly diagnosed DLBCL in elderly patients: Updated results of the phase II TREND trial

Gao Yan, Xue-Ping Li, Xuan-Ye Zhang, Xiaoxiao Wang, Bing BAI, Li-Qin Ping, Qichun Cai, Jia-Ling Zhuang, Huiqiang Huang

Blood (2025) 146 (Supplement 1): 1965.

https://doi.org/10.1182/blood-2025-1965

Published: 2025

Journal Articles

A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

Blood (2025) 145 (14): 1526–1535.

https://doi.org/10.1182/blood.2024026401

Published: 2025

Includes: Supplemental data

Journal Articles

The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) As the First-Line Induction Therapy Followed By Autologous Stem Cell Transplantation in Newly Diagnosed Primary Central Nervous System Lymphoma

Haichen Wei, Lijie Xing, Dan Liu, Hui Wang, Ping Li, Zengjun Li

Blood (2024) 144 (Supplement 1): 1742.

https://doi.org/10.1182/blood-2024-204844

Published: 2024

Journal Articles

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma with MYC +

Lili Zhou, Shiguang Ye, Ping Li, Bing Li, Yan Lu, Shaoguang Li, Aibin Liang

Blood (2024) 144 (Supplement 1): 6524.

https://doi.org/10.1182/blood-2024-208414

Published: 2024

Journal Articles

Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement

Gao Yan, Xue-Ping Li, Xiaoxiao Wang, Xiaoyu Hong, Bing Bai, Xuanye Zhang, Jialing Zhuang, Huiqiang Huang

Blood (2024) 144 (Supplement 1): 3071.

https://doi.org/10.1182/blood-2024-207630

Published: 2024

Journal Articles

Clinical Evaluation of Fast-in-Time (FIT) Anti-CD19 CAR T-a Non-Viral, 2-Day Rapid Manufacture CAR T-Cell Therapy for B-Cell Malignancies

Ping Li, Jian Ge, Shiguang Ye, Lili Zhou, Yiming Gong, Huaying Ruan, Hosein Kouros-Mehr, Aibin Liang

Blood (2024) 144 (Supplement 1): 3475.

https://doi.org/10.1182/blood-2024-199236

Published: 2024

Journal Articles

Exploring the Mechanism of Chromatin Spatial Structure Changes and Transcriptional Regulation in Age-Related Clonal Hematopoiesis Caused By DNMT3A Mutations Using Chromatin Capture Technology

Yujun Dai, Xue-Ping Li, Yang Liang

Blood (2024) 144 (Supplement 1): 192.

https://doi.org/10.1182/blood-2024-200714

Published: 2024

Journal Articles

Autologous Transplant Consolidation Vs. Immunotherapy Maintanance Therapy in Patients with Relapsed or Refractory NK/T Lymphoma Treated While in Complete Remission

Gao Yan, Xue-Ping Li, Bing Bai, Xiaoxiao Wang, Xuanye Zhang, Huiqiang Huang

Blood (2024) 144 (Supplement 1): 3066.

https://doi.org/10.1182/blood-2024-205253

Published: 2024

Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Blood (2024) 144 (Supplement 1): 5115.

https://doi.org/10.1182/blood-2024-207186

Published: 2024

Journal Articles

To Investigate the Efficacy of Long-Term Step-Reduction Methylprednisolone in the Treatment of Severe Persistent Thrombocytopenia after CAR-T Cell Therapy

Haiyan Jiang, Ping Li, Lili Zhou, Shiguang Ye, Xiu Luo, Yan Lu, Bin Xue, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6934.

https://doi.org/10.1182/blood-2023-188386

Published: 2023

Journal Articles

Methotrexate in Combination with Orelabrutinib, Thiotepa, and Rituximab (R-MTO) Followed By Autologous Stem-Cell Transplant for Primary Central Nervous System Lymphoma Treatment

Lijie Xing, Haichen Wei, Dan Liu, Hui Wang, Ping Li, Linna Xie, Zengjun Li

Blood (2023) 142 (Supplement 1): 6228.

https://doi.org/10.1182/blood-2023-186219

Published: 2023

Journal Articles

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Blood (2023) 142 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2023-190712

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL

A multicenter, single-arm study of camrelizumab combined with rituximab followed by R-CHOP as first-line treatment for young patients with primary extranodal diffuse large B-cell lymphoma: The credit trial

A real world study of inotuzumab ozogamicin for the treatment of B-cell acute lymphoblastic leukemia: Multi-center result from SH-ALL group

Efficacy and safety of a fully human BCMA CAR T-cell therapy for high-risk newly diagnosed transplant-ineligible multiple myeloma: Updated results from an open label, single-arm，phase 1 study（fumanba-2）

Efficacy and safety of chidamide and Bruton tyrosine kinase inhibitors combination therapy in relapsed/refractory diffuse large B-cell lymphoma

primary efficacy and safety of first-line R-MTO regimen (rituximab, methotrexate, thiotepa, and orelabrutinib) followed by autologous hematopoietic stem cell transplantation in PCNSL

Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study

Combination anti-PD1 antibody and rituximab followed by R-CHOP for newly diagnosed DLBCL in elderly patients: Updated results of the phase II TREND trial

A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) As the First-Line Induction Therapy Followed By Autologous Stem Cell Transplantation in Newly Diagnosed Primary Central Nervous System Lymphoma

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma with MYC +

Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement

Clinical Evaluation of Fast-in-Time (FIT) Anti-CD19 CAR T-a Non-Viral, 2-Day Rapid Manufacture CAR T-Cell Therapy for B-Cell Malignancies

Exploring the Mechanism of Chromatin Spatial Structure Changes and Transcriptional Regulation in Age-Related Clonal Hematopoiesis Caused By DNMT3A Mutations Using Chromatin Capture Technology

Autologous Transplant Consolidation Vs. Immunotherapy Maintanance Therapy in Patients with Relapsed or Refractory NK/T Lymphoma Treated While in Complete Remission

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

To Investigate the Efficacy of Long-Term Step-Reduction Methylprednisolone in the Treatment of Severe Persistent Thrombocytopenia after CAR-T Cell Therapy

Methotrexate in Combination with Orelabrutinib, Thiotepa, and Rituximab (R-MTO) Followed By Autologous Stem-Cell Transplant for Primary Central Nervous System Lymphoma Treatment

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only